concentration, the first extract is further extracted for obtaining a second extract having a second jujuba cAMP concentration, the second jujuba cAMP concentration is higher than the first jujuba cAMP concentration, and the second extract is being a raw material in the pharmaceutical composition.

6. A pharmaceutical composition for treating at least one of a depression and an anxiety disorder, comprising:

a ginsenoside having an Rg1 and an Rb1; and

a glycyrrhizically related acid being one selected from a group consisting of a glycyrrhizic acid, a glycyrrhetinic acid and a combination thereof.

7. The pharmaceutical composition according to claim 6 comprising 2 ~ 25 parts by weight of the ginsenoside and 3 ~ 46 parts by weight of the glycyrrhizically related acid.

8. The pharmaceutical composition according to claim 7 comprising 4 ~ 12 parts by weight of the ginsenoside and 5 ~ 15 parts by weight of the glycyrrhizically related acid.

9. The pharmaceutical composition according to claim 6 further comprising at least one of a pharmacologically acceptable carrier and an additive, and being manufactured as one of a healthy food and a nutrient supplement.

10. The pharmaceutical composition according to claim 6 having a dosage form selected from a group consisting of a tablet, a capsule, a powder, a pill, a dust, a solution, a microcapsule, a suspension, an emulsion, a particle, a dropping pill and a roll.

~~11. The pharmaceutical composition of any one of claims 1 to 10 substantially as hereinbefore described with reference to the preferred embodiments and accompanying figures.~~